Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | IPO9 | CTRPv2 | pan-cancer | AAC | 0.22 | 6e-11 |
mRNA | SUGP2 | CTRPv2 | pan-cancer | AAC | 0.22 | 6e-09 |
mRNA | SMARCC1 | CTRPv2 | pan-cancer | AAC | 0.23 | 9e-10 |
mRNA | ARHGAP19-SLIT1 | CTRPv2 | pan-cancer | AAC | 0.23 | 4e-09 |
mRNA | KHDRBS1 | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-11 |
mRNA | SFPQ | CTRPv2 | pan-cancer | AAC | 0.23 | 4e-11 |
mRNA | BEND3 | CTRPv2 | pan-cancer | AAC | 0.23 | 3e-11 |
mRNA | PRR36 | CTRPv2 | pan-cancer | AAC | 0.23 | 1e-11 |
mRNA | NASP | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-12 |
mRNA | ARHGAP45 | CTRPv2 | pan-cancer | AAC | 0.23 | 6e-07 |